首页 > 最新文献

Pain Practice最新文献

英文 中文
Authors' response to the letter to the editor on: Differences in efficacy and safety between intrathecal infusion devices in cancer pain. 作者对致编辑的信的回复:不同鞘内输注装置治疗癌痛的疗效和安全性差异。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-10-02 DOI: 10.1111/papr.13422
Diego Díaz-Rodríguez, Isabel M Fontán-Atalaya, Estefanía Peralta-Espinosa, Bartolomé Fernández-Torres
{"title":"Authors' response to the letter to the editor on: Differences in efficacy and safety between intrathecal infusion devices in cancer pain.","authors":"Diego Díaz-Rodríguez, Isabel M Fontán-Atalaya, Estefanía Peralta-Espinosa, Bartolomé Fernández-Torres","doi":"10.1111/papr.13422","DOIUrl":"https://doi.org/10.1111/papr.13422","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
12. Vascular pain: Ischemic pain in the extremities and Raynaud's syndrome 12. 血管性疼痛 四肢缺血性疼痛和雷诺综合征。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-30 DOI: 10.1111/papr.13421
Antal van der Gaag, Steven P Cohen, Milan P Stojanovic, Frank J P M Huygen, Jan Willem Kallewaard

Introduction: Peripheral artery diseases (PAD) and Raynaud's syndrome are associated with substantial morbidity. PAD, through the restriction of blood flow to the extremities, may lead to critical limb ischemia with symptoms of pain at rest which may eventually progress to severe limb ischemia with gangrene. This serious and painful clinical condition requires extensive medical care, is limb-threatening and, in case of delayed or unsuccessful treatment, is associated with a high mortality rate. In Raynaud's syndrome, the blood supply to certain parts of the body, usually the fingers and toes and less frequently the nose or ears, is restricted because of vasculopathy of the smaller vessels at acral sites. Under certain circumstances, with cold as the most well-known provoking factor, blood flow restriction occurs, leading to demarcated color changes and symptoms such as pain, paresthesia, and numbness. In severe cases of Raynaud syndrome tissue ischemia may lead to necrosis and the need for amputation of the affected area.

Methods: In this narrative review, the literature on the diagnosis and interventional pain treatment of PAD and Raynaud's syndrome was updated and summarized.

Objectives: This review focused on interventional pain treatment. In PAD, the effects of the intervention on limb salvage, ulcer healing, and ischemic pain were summarized. Additionally, results with respect to skin microcirculation and quality of life were reported if available. In Raynaud's syndrome, we focused on the effect of the intervention on peripheral blood flow metrics and pain intensity during attacks.

Results: In PAD, prevention and treatment of risk factors are important. Initially, conservative treatment and pharmacological therapy are preferred first-line therapies. However, when disease progression occurs, interventional management may be considered. The literature search yielded conflicting evidence for sympathectomy as a treatment for PAD. Spinal cord stimulation (SCS) as a treatment modality for advanced PAD had high-quality evidence for limb salvage in subgroups of patients but conflicting evidence for other outcome measures such as pain, wound healing, and quality of life. The literature search for interventional pain management in Raynaud's syndrome was limited to only one randomized controlled trial (RCT) studying the effect of thoracic sympathectomy. This study had several limitations and hence the level of evidence for this interventional treatment is very low. No RCTs studying SCS in patients with Raynaud's syndrome were found.

Conclusions: In both PAD and Raynaud's syndrome, additional RCTs are needed to substantiate interventional (pain) management and bolster the evidence base for sympathectomy and SCS as treatment options.

导言:外周动脉疾病(PAD)和雷诺综合征与严重的发病率有关。PAD 通过限制肢体血流,可能导致肢体严重缺血,并伴有静息时疼痛的症状,最终可能发展为肢体严重缺血并伴有坏疽。这种严重而痛苦的临床症状需要广泛的医疗护理,会危及肢体,如果治疗延误或不成功,死亡率很高。在雷诺氏综合征中,身体某些部位(通常是手指和脚趾,较少见的是鼻子或耳朵)的血液供应受到限制,原因是尖锐部位的小血管发生病变。在某些情况下,最常见的诱发因素是寒冷,血流受限会导致明显的颜色变化以及疼痛、麻痹和麻木等症状。在雷诺综合征的严重病例中,组织缺血可能导致坏死,需要截肢:在这篇叙事性综述中,对有关 PAD 和雷诺综合征的诊断和介入性疼痛治疗的文献进行了更新和总结:本综述侧重于介入性疼痛治疗。在 PAD 中,总结了干预对肢体挽救、溃疡愈合和缺血性疼痛的影响。此外,还报告了皮肤微循环和生活质量方面的结果(如果有的话)。对于雷诺氏综合征,我们重点研究了干预措施对外周血流指标和发作时疼痛强度的影响:结果:对于 PAD,预防和治疗危险因素非常重要。最初,保守治疗和药物治疗是首选的一线疗法。然而,当疾病进展时,可考虑进行介入治疗。文献检索结果显示,交感神经切除术作为 PAD 治疗方法的证据相互矛盾。脊髓刺激(SCS)作为晚期 PAD 的一种治疗方式,在亚组患者的肢体挽救方面有高质量的证据,但在疼痛、伤口愈合和生活质量等其他结局指标方面的证据相互矛盾。有关雷诺氏综合征介入性疼痛治疗的文献搜索仅限于一项研究胸交感神经切除术效果的随机对照试验(RCT)。该研究存在一些局限性,因此这种介入治疗的证据水平很低。没有发现研究雷诺氏综合征患者SCS的随机对照试验:结论:对于 PAD 和雷诺氏综合征,需要更多的 RCT 来证实介入性(疼痛)治疗,并加强交感神经切除术和 SCS 作为治疗方案的证据基础。
{"title":"12. Vascular pain: Ischemic pain in the extremities and Raynaud's syndrome","authors":"Antal van der Gaag, Steven P Cohen, Milan P Stojanovic, Frank J P M Huygen, Jan Willem Kallewaard","doi":"10.1111/papr.13421","DOIUrl":"10.1111/papr.13421","url":null,"abstract":"<p><strong>Introduction: </strong>Peripheral artery diseases (PAD) and Raynaud's syndrome are associated with substantial morbidity. PAD, through the restriction of blood flow to the extremities, may lead to critical limb ischemia with symptoms of pain at rest which may eventually progress to severe limb ischemia with gangrene. This serious and painful clinical condition requires extensive medical care, is limb-threatening and, in case of delayed or unsuccessful treatment, is associated with a high mortality rate. In Raynaud's syndrome, the blood supply to certain parts of the body, usually the fingers and toes and less frequently the nose or ears, is restricted because of vasculopathy of the smaller vessels at acral sites. Under certain circumstances, with cold as the most well-known provoking factor, blood flow restriction occurs, leading to demarcated color changes and symptoms such as pain, paresthesia, and numbness. In severe cases of Raynaud syndrome tissue ischemia may lead to necrosis and the need for amputation of the affected area.</p><p><strong>Methods: </strong>In this narrative review, the literature on the diagnosis and interventional pain treatment of PAD and Raynaud's syndrome was updated and summarized.</p><p><strong>Objectives: </strong>This review focused on interventional pain treatment. In PAD, the effects of the intervention on limb salvage, ulcer healing, and ischemic pain were summarized. Additionally, results with respect to skin microcirculation and quality of life were reported if available. In Raynaud's syndrome, we focused on the effect of the intervention on peripheral blood flow metrics and pain intensity during attacks.</p><p><strong>Results: </strong>In PAD, prevention and treatment of risk factors are important. Initially, conservative treatment and pharmacological therapy are preferred first-line therapies. However, when disease progression occurs, interventional management may be considered. The literature search yielded conflicting evidence for sympathectomy as a treatment for PAD. Spinal cord stimulation (SCS) as a treatment modality for advanced PAD had high-quality evidence for limb salvage in subgroups of patients but conflicting evidence for other outcome measures such as pain, wound healing, and quality of life. The literature search for interventional pain management in Raynaud's syndrome was limited to only one randomized controlled trial (RCT) studying the effect of thoracic sympathectomy. This study had several limitations and hence the level of evidence for this interventional treatment is very low. No RCTs studying SCS in patients with Raynaud's syndrome were found.</p><p><strong>Conclusions: </strong>In both PAD and Raynaud's syndrome, additional RCTs are needed to substantiate interventional (pain) management and bolster the evidence base for sympathectomy and SCS as treatment options.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Caution: Ultrasound-guided intercostal nerve block is not entirely safe. 注意事项超声引导下的肋间神经阻滞并非完全安全。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-30 DOI: 10.1111/papr.13420
Yuko Nakano, Rieko Oishi, Satoki Inoue
{"title":"Caution: Ultrasound-guided intercostal nerve block is not entirely safe.","authors":"Yuko Nakano, Rieko Oishi, Satoki Inoue","doi":"10.1111/papr.13420","DOIUrl":"https://doi.org/10.1111/papr.13420","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidural venous plexus engorgement: A rare cause of low back pain. 硬膜外静脉丛充血:腰背痛的罕见病因
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-27 DOI: 10.1111/papr.13419
Pelin Analay, Alp Çetin
{"title":"Epidural venous plexus engorgement: A rare cause of low back pain.","authors":"Pelin Analay, Alp Çetin","doi":"10.1111/papr.13419","DOIUrl":"https://doi.org/10.1111/papr.13419","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142351774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comparison of steroid dose with or without local anesthetic in lumbar interlaminar epidural steroid injections. 腰椎层间硬膜外类固醇注射中使用或不使用局部麻醉剂的类固醇剂量比较。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-20 DOI: 10.1111/papr.13410
Robert Chow, Jessica Ng, Melanie Wood, David Yanez, Zili He, Kanishka Rajput

Introduction: Epidural steroid injections (ESIs) are commonly used as a treatment for lumbar radiculopathy. Currently, most research on comparative efficacy of various steroids in epidural steroid injections is focused on transforaminal ESIs (TFESIs). Through this study, we aimed to compare various steroid doses with or without local anesthetic in interlaminar ESIs (ILESIs).

Methods: We reviewed charts for all adult patients who received ILESIs identified by CPT code 62323 between January 2017 to April 2021. Baseline demographic data including age, sex, BMI, and smoking status were recorded. NRS pain scores before the injection and percentage of pain relief at 1-month follow-up were recorded. We compared percentage of patients reporting pain relief at 1 month follow-up of low-dose dexamethasone alone (5 mg), to low-dose dexamethasone mixed with local anesthetic, and to high-dose dexamethasone (10 mg) mixed with local anesthetic, specifically for ILESIs.

Results: Data were available for 311 patients. There was no significant difference in pain relief between the 3 groups at 1 month follow-up. The majority of patients had moderate to significant improvement in pain, supporting the use of ILESIs. Moreover, low-dose steroid with local anesthetic was found to be as efficacious as high-dose steroid alone. Although not statistically significant, the addition of local anesthetic to low-dose or high-dose steroid increased the percentage of patients reporting moderate to significant pain relief.

Conclusion: ILESIs with non-particulate steroids provide moderate to significant pain improvement in the short term, with low-dose steroid mixed with local anesthetic being as efficacious as a high-dose steroid.

简介:硬膜外类固醇注射(ESI)是治疗腰椎病的常用方法。目前,有关硬膜外类固醇注射中各种类固醇疗效比较的研究大多集中在经椎间孔硬膜外类固醇注射(TFESIs)上。通过这项研究,我们旨在比较各种类固醇剂量在进行层间硬膜外类固醇注射(ILESI)时使用或不使用局麻药的效果:我们查阅了 2017 年 1 月至 2021 年 4 月期间接受 CPT 代码 62323 识别的 ILESI 的所有成年患者的病历。记录了基线人口统计学数据,包括年龄、性别、体重指数和吸烟状况。记录了注射前的 NRS 疼痛评分和随访 1 个月时疼痛缓解的百分比。我们比较了单独使用低剂量地塞米松(5 毫克)、低剂量地塞米松与局麻药混合使用以及高剂量地塞米松(10 毫克)与局麻药混合使用(特别是针对 ILESIs)的患者在随访 1 个月时报告疼痛缓解的百分比:结果:311 名患者的数据可用。随访 1 个月时,3 组患者的疼痛缓解程度无明显差异。大多数患者的疼痛得到了中度到明显的改善,这支持了 ILESIs 的使用。此外,低剂量类固醇联合局麻药的疗效与单独使用高剂量类固醇的疗效相同。虽然没有统计学意义,但在低剂量或高剂量类固醇中添加局麻药可增加中度至明显缓解疼痛的患者比例:结论:使用无颗粒类固醇的ILESI可在短期内中度至明显改善疼痛,低剂量类固醇与局麻药混合使用的疗效与高剂量类固醇相同。
{"title":"A comparison of steroid dose with or without local anesthetic in lumbar interlaminar epidural steroid injections.","authors":"Robert Chow, Jessica Ng, Melanie Wood, David Yanez, Zili He, Kanishka Rajput","doi":"10.1111/papr.13410","DOIUrl":"https://doi.org/10.1111/papr.13410","url":null,"abstract":"<p><strong>Introduction: </strong>Epidural steroid injections (ESIs) are commonly used as a treatment for lumbar radiculopathy. Currently, most research on comparative efficacy of various steroids in epidural steroid injections is focused on transforaminal ESIs (TFESIs). Through this study, we aimed to compare various steroid doses with or without local anesthetic in interlaminar ESIs (ILESIs).</p><p><strong>Methods: </strong>We reviewed charts for all adult patients who received ILESIs identified by CPT code 62323 between January 2017 to April 2021. Baseline demographic data including age, sex, BMI, and smoking status were recorded. NRS pain scores before the injection and percentage of pain relief at 1-month follow-up were recorded. We compared percentage of patients reporting pain relief at 1 month follow-up of low-dose dexamethasone alone (5 mg), to low-dose dexamethasone mixed with local anesthetic, and to high-dose dexamethasone (10 mg) mixed with local anesthetic, specifically for ILESIs.</p><p><strong>Results: </strong>Data were available for 311 patients. There was no significant difference in pain relief between the 3 groups at 1 month follow-up. The majority of patients had moderate to significant improvement in pain, supporting the use of ILESIs. Moreover, low-dose steroid with local anesthetic was found to be as efficacious as high-dose steroid alone. Although not statistically significant, the addition of local anesthetic to low-dose or high-dose steroid increased the percentage of patients reporting moderate to significant pain relief.</p><p><strong>Conclusion: </strong>ILESIs with non-particulate steroids provide moderate to significant pain improvement in the short term, with low-dose steroid mixed with local anesthetic being as efficacious as a high-dose steroid.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semi‐invasive therapies for pain in knee osteoarthritis: A systematic review and network meta‐analysis 治疗膝关节骨关节炎疼痛的半侵入性疗法:系统综述和网络荟萃分析
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-13 DOI: 10.1111/papr.13404
Siew‐Li Goh, Melissa Wee Chong, Jerri Ling, Zulkarnain Jaafar, Zhuang‐Li Lim, May‐Yann Yau, Terence Ong, Jim Richards
BackgroundThe increasing number of semi‐invasive pain therapies in knee osteoarthritis poses challenges in decision‐making. This review aimed to simultaneously compare established intra‐articular therapies with newer peri‐articular therapies and explore effect modifiers.MethodsRandomized controlled trials were searched from five electronic databases without date or language restrictions. Study selection and data extraction of reports, retrieved up to May 2024, were performed independently by paired assessors. The primary outcome was 6‐month pain score. Nine treatments were included. The effect size (ES) for each treatment, relative to placebo, was estimated using standardized means difference and expressed with 95% confidence intervals (CI). The rigor of results was evaluated with subgroup/sensitivity analyses.ResultsA total of 111 studies (14,695 participants) were included, with intra‐articular hyaluronic acid having the greatest number of participants. Neuroablation demonstrated the greatest ES (1.08, 95% CI: 0.07, 2.10). While platelet‐rich plasma (PRP) ranked second (ES: 0.75, 95% CI: 0.28, 1.22), it was the only intervention demonstrating statistically significant effect at 3, 6, and 12 months. However, this statistical significance was lost in some sensitivity analyses. Larger estimates for biologics and PRP compared with prolotherapy, steroid, and hyaluronic acid injections were consistently observed across different timepoints and in multiple sensitivity analyses. Generally, no statistically significant difference was found between the nine types of therapies.ConclusionAlthough there is robust evidence suggesting greater efficacy of PRP, potentially including biologics, over other interventions, future research is needed to identify the phenotype or patient subgroup that would benefit most from PRP.
背景膝关节骨关节炎的半侵入性疼痛疗法越来越多,给决策带来了挑战。本综述旨在同时比较既有的关节内疗法和较新的关节周围疗法,并探讨效果调节因素。方法在五个电子数据库中检索随机对照试验,无日期或语言限制。截至 2024 年 5 月检索到的研究选择和报告数据提取均由配对评估员独立完成。主要结果为 6 个月的疼痛评分。共纳入九种治疗方法。每种疗法相对于安慰剂的效应大小 (ES) 采用标准化均值差估算,并用 95% 置信区间 (CI) 表示。结果 共纳入了 111 项研究(14,695 人参与),其中关节内透明质酸的参与人数最多。神经消融的ES值最大(1.08,95% CI:0.07,2.10)。富血小板血浆 (PRP) 排名第二(ES:0.75,95% CI:0.28,1.22),是唯一一种在 3、6 和 12 个月时具有显著统计学效果的干预方法。然而,在一些敏感性分析中,这种统计学意义消失了。在不同的时间点和多个敏感性分析中,均持续观察到生物制剂和 PRP 与增殖疗法、类固醇和透明质酸注射相比,具有更大的估计值。结论虽然有确凿证据表明 PRP(可能包括生物制剂)比其他干预措施具有更高的疗效,但未来仍需开展研究,以确定从 PRP 中获益最多的表型或患者亚群。
{"title":"Semi‐invasive therapies for pain in knee osteoarthritis: A systematic review and network meta‐analysis","authors":"Siew‐Li Goh, Melissa Wee Chong, Jerri Ling, Zulkarnain Jaafar, Zhuang‐Li Lim, May‐Yann Yau, Terence Ong, Jim Richards","doi":"10.1111/papr.13404","DOIUrl":"https://doi.org/10.1111/papr.13404","url":null,"abstract":"BackgroundThe increasing number of semi‐invasive pain therapies in knee osteoarthritis poses challenges in decision‐making. This review aimed to simultaneously compare established intra‐articular therapies with newer peri‐articular therapies and explore effect modifiers.MethodsRandomized controlled trials were searched from five electronic databases without date or language restrictions. Study selection and data extraction of reports, retrieved up to May 2024, were performed independently by paired assessors. The primary outcome was 6‐month pain score. Nine treatments were included. The effect size (ES) for each treatment, relative to placebo, was estimated using standardized means difference and expressed with 95% confidence intervals (CI). The rigor of results was evaluated with subgroup/sensitivity analyses.ResultsA total of 111 studies (14,695 participants) were included, with intra‐articular hyaluronic acid having the greatest number of participants. Neuroablation demonstrated the greatest ES (1.08, 95% CI: 0.07, 2.10). While platelet‐rich plasma (PRP) ranked second (ES: 0.75, 95% CI: 0.28, 1.22), it was the only intervention demonstrating statistically significant effect at 3, 6, and 12 months. However, this statistical significance was lost in some sensitivity analyses. Larger estimates for biologics and PRP compared with prolotherapy, steroid, and hyaluronic acid injections were consistently observed across different timepoints and in multiple sensitivity analyses. Generally, no statistically significant difference was found between the nine types of therapies.ConclusionAlthough there is robust evidence suggesting greater efficacy of PRP, potentially including biologics, over other interventions, future research is needed to identify the phenotype or patient subgroup that would benefit most from PRP.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"55 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevated lead impedances in spinal cord stimulation systems 脊髓刺激系统的导联阻抗升高
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-13 DOI: 10.1111/papr.13415
Alaa Abd‐Elsayed, Christopher Gilligan
{"title":"Elevated lead impedances in spinal cord stimulation systems","authors":"Alaa Abd‐Elsayed, Christopher Gilligan","doi":"10.1111/papr.13415","DOIUrl":"https://doi.org/10.1111/papr.13415","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"20 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain 低能量差分靶向多路复用体外脊髓刺激疗法衍生物可在 12 个月内减轻慢性背痛和/或腿痛患者的疼痛并改善其生活质量
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13407
Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue
IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.
导言减少能量的脊髓刺激(SCS)方法有可能通过减少设备充电时间或延长设备寿命来影响患者使用可充电和不可充电 SCS 设备的体验。这项前瞻性多中心研究评估了差分靶向多路复用(DTM)耐力疗法(一种降低能量的 DTM SCS 衍生物)的安全性、有效性和实际能量使用情况。方法基线时报告总体疼痛视觉模拟评分(VAS)≥6/10 厘米、Oswestry 残疾指数评分(满分 100 分,21-80 分)为中度至重度慢性顽固性背部和/或腿部疼痛的受试者均符合条件。评估访问在设备激活后的 1、3、6 和 12 个月进行。结果2020 年 11 月至 2021 年 6 月期间,57 名受试者在美国的 12 个地点注册,35 名受试者植入了可充电 SCS 装置,27 名受试者完成了 12 个月的访问。在 3 个月的随访中,受试者的总体疼痛平均比基线减轻了 50.4%,并持续了 12 个月。其他结果包括总体、背部和腿部疼痛强度、生活质量、残疾程度、治疗满意度、安全性和当前电池使用情况的变化,这些结果都显示在 12 个月的随访中。临床有效的减能量 SCS 衍生物有可能通过降低充电要求或延长设备寿命来影响患者的体验。
{"title":"Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain","authors":"Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue","doi":"10.1111/papr.13407","DOIUrl":"https://doi.org/10.1111/papr.13407","url":null,"abstract":"IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"390 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
10. Complex regional pain syndrome 10.复杂区域疼痛综合征
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13413
Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen
IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.
导言 复杂区域性疼痛综合征(CRPS)是一种临床疾病,可在手术或创伤后发生。根据最突出的潜在病理生理机制,CRPS 可分为不同的亚型,即炎症型、神经痉挛/神经病理性型、血管运动型和运动型。根据亚型的不同,可以采用个性化的治疗方法。如果保守治疗不足或无效,可能会建议采用更具侵入性的治疗方法。本文概述了对CRPS的最新见解,并讨论了最常见的侵入性治疗方法。结果双膦酸盐可有效治疗炎症亚型,而氯胺酮可缓解非痉挛性/神经病理性亚型的疼痛。交感神经阻滞可有效解决血管运动障碍。对于有难治性症状的患者,神经刺激是一种可行的选择,因为它具有针对所有亚型的多机制特性。结论 CRPS 是一种使人衰弱的疾病,病程难以预测。治疗效果因人而异。当保守治疗效果不佳时,建议根据潜在的亚型逐步过渡到侵入性治疗。
{"title":"10. Complex regional pain syndrome","authors":"Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen","doi":"10.1111/papr.13413","DOIUrl":"https://doi.org/10.1111/papr.13413","url":null,"abstract":"IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"19 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement. 较小的胸椎管直径与脊髓刺激器桨状导联线置入后的胸椎根性病变和腹痛有关。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-06 DOI: 10.1111/papr.13414
Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan

Introduction: It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.

Objective: This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.

Methods: Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.

Results: Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.

Conclusion: A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.

导言:植入胸椎脊髓刺激器(SCS)桨状导线后,患者术后出现神经功能缺损、胸椎根性病变、腹痛或下肢麻痹的情况并不少见。较小的胸椎管直径曾与术后神经功能缺损有关:本影像学研究探讨了 SCS 术后除神经功能缺损外的其他神经症状是否与胸椎管直径相关:确定了 2018 年 1 月至 2023 年 3 月间因 SCS 桨状导联置入而接受胸椎椎板切开术的患者。术前胸椎管直径通过 MRI 或 CT 成像在 T5/6 至 T11/12 的矢状面上进行测量。对术后出现和未出现新的神经系统症状的患者的胸椎管直径进行比较:结果:246 名患者接受了胸椎椎板切除术,以植入 SCS 桨状导联。分别有 3.7%(9/246)、2.8%(7/246)和 2.0%(5/246)的患者出现胸椎根性病变、腹痛和下肢麻痹。无神经系统主诉、胸椎根性病变、腹痛和下肢麻痹的患者的胸椎管平均直径分别为 13.1 毫米、12.0 毫米(p 结论:胸椎管直径越小,下肢麻痹越严重:较小的胸椎管直径与术后胸椎根性病变和腹痛有关。我们认为,为 SCS 导联创造足够空间的手术规划对于预防术后神经功能缺损、胸椎根性病变和腹痛等症状至关重要。
{"title":"Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement.","authors":"Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan","doi":"10.1111/papr.13414","DOIUrl":"https://doi.org/10.1111/papr.13414","url":null,"abstract":"<p><strong>Introduction: </strong>It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.</p><p><strong>Objective: </strong>This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.</p><p><strong>Methods: </strong>Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.</p><p><strong>Results: </strong>Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.</p><p><strong>Conclusion: </strong>A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pain Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1